PRIORITIZING HEALTH IN U.S. TRADE POLICY: A CASE EXAMPLE.

Slides:



Advertisements
Similar presentations
Differential Pricing: Reconciling R&D, IP and Access Patricia M. Danzon PhD The Wharton School University of Pennsylvania.
Advertisements

Policy, Politics and Power: Building – And Passing – Our Health Access Law Ellen R. Shaffer PhD MPH Center for Policy Analysis
Fixing the U.S. Congress by Embracing Earmarks John Hudak, Ph.D. Fellow, Center for Effective Public Management The Brookings Institution E:
Understanding patents & medicine access the WTO, free trade agreements & patent law.
Unit 13 International Marketing
Tobacco Industry Expropriates Intellectual Property Rules Ellen R. Shaffer, PhD MPH Joseph Brenner, MA CPATH Center for Policy Analysis on Trade and Health.
Influencing the Political Environment
International Trade and Medicine Prices Mike Palmedo Research Coordinator Project on Information Justice and Intellectual Property Washington College of.
The Korus FTA Will Lead to Higher Drug Prices in Korea
Intellectual Property and Bilateral Trade Agreements Moving towards effective participation.
4.02 Exemplify the 4 types of economic systems, & the effects of economic integration on international marketing YouTube clip.
More on Generic Drugs Global Classrooms 2013 Rachel Hunkler.
International Max Planck Research School for Competition and Innovation WIPO – Owais Hassan Shaikh IMPRS-CI 2010 Data Exclusivity in Free Trade.
Medicines & Related Substances Amendment Bill: Protecting the Nation’s Health “The State must take reasonable legislative and other measures, within its.
North American Free Trade Agreement MEG AND ALICIA.
Under Threat: New Trade Deals and Construction Workers (June 2003) Prepared for the By the Resource Center of the Americas & Labor Education Service, University.
Vermont Commission on International Trade and State Sovereignty Overview of International Trade and Its Impact on Vermont’s Health Care Vermont’s Health.
Washington D.C., USA, July 2012www.aids2012.org Intellectual Property-related challenges: A Latin America Perspective GraciaVioleta Ross
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
Restrictions on exports of medicine: irrational public policy, backdoor efforts to marginalize compulsory licensing, or Northern protectionism? James Love.
Opportunities in the Pharma Industry Industry sales: $346B Industry sales growth: 42% during the past five years Future growth: 8-10% growth per year;
Australia-US Free Trade Agreement Overview. Outline Bilateral trade strategy US Agenda Australian agenda Community campaign Campaign achievements Campaign.
The FTC, Pharmaceuticals, Antitrust & IP: A Grab Bag October 23, 2008 This presentation was prepared from public sources. The views expressed herein do.
Chapter Twenty-two The Nature of American Democracy.
Japan-EU EPA Negotiation: Lessons from EU-South Korea FTA EU Institute in Japan, Kansai Graduate School of Economics, Kobe University Dr. Prof. YOSHII.
TOPIC #7 Canada and International Trade Agreements.
Lyndon B. Johnson’s Great Society What domestic policies does LBJ bring to the White House?
International Business Chapter Seven Regional Economic Integrations and Cooperative Agreements International Business 10e Daniels/Radebaugh/Sullivan 2004.
An Introduction to Fast Track The Oregon Fair Trade Campaign OR-FTC.
MFJ International, LLC A Global Consulting Firm “FTAs and Pharmaceuticals: a hijacked process?” M. Fabiana Jorge CPTECH November 16, 2006.
U.S.-Australia Free Trade Agreement Launched in November 2002, most important formal advance in U.S.- Australian relations since ANZUS Treaty Bush/Howard.
Parallel Trade and the Pricing of Pharmaceutical Products Frank Müller-Langer Conference on „Health Economics and the Pharmaceutical Industry“
Are free trade agreements harmful to the U.S economy?
April 1, 2010 Lobbying: The Scarlet “L” or Democracy in Action?
APS Day 31 Agenda.  What is politics? 1) the art or science of obtaining and maintaining power, and 2) the art or science of governing – ruling and controlling.
HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida
Pharmaceuticals – a recap Discuss the view that “drugs companies are not fully addressing the needs of the world’s poorest people.”
Ellen ‘t Hoen Médecins sans Frontières
© 2004 Moses & Singer LLP HIPAA and Patient Privacy Issues Raised by the New Medicare Prescription Drug Program National Medicare Prescription Drug Congress.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA RECAP ON PROCEEDINGS OF DAY 1 George Mpundu.
Tensions between Brazil and the United States
The World Trade Organisation. What is the WTO?  Multilateral body responsible for overseeing the conduct of international trade.
The Legislative Branch: Committees and Leadership Unit 5: The Legislative Branch.
Kennedy’s New Frontier New Frontier is Kennedy’s plan in changing the nation. Most people in the 1960’s did not want reform. Many Southern Democrats joined.
COMMITTEES IN CONGRESS NOW, THE REAL WORK GETS DONE…
The Intellectual Property Provisions of Recent US FTAs CARSTEN FINK Video Conference for Andean Countries on Intellectual Property Rights, May 4, 2005.
International Trade Chapter #4.
Overview of the New Medicare-Endorsed Prescription Drug Discount Card Program The Intersection of Business Strategy and Public Policy The Health Strategies.
U.S. Health Care System – Jenny Lee INEKO, Michigan Law School Student June 14, 2004.
TRIPS-Plus Pressures: Trade Agreements, and New Trade Policy Prof. Brook K. Baker OSI Kiev – IPRs & A2M, Sept. 16, 2009.
CAFTA: Boon to Innovation, or Obstacle for Women? Ellen R. Shaffer PhD MPH, Joe Brenner MA Center for Policy Analysis on Trade and Health (CPATH)
Intellectual Property Negotiations Between the United States and Colombia, Peru and Equator for a Free Trade Agreement, Relating to Medicine James Love.
Competition and Intellectual Property Protection in the Pharmaceutical Sector Alexey Ivanov Director, HSE-Skolkovo Institute for Law and Development Director,
Chapter 20-Section 3-The Great Society. LBJ’s Path to Power 1963-VP LBJ comes to power – Southerner (From Texas) – Long time senator, supported the New.
NAFTA, CAFTA and Access to Medicines and Food Security in Latin America International Aids Conference Session “Globalization and FTAs: their impact, access.
TRADE NEGOTIATION ON PHARMACETICALS PRESENTED BY CHOGO,MALESO (092SIS10).
International Trade Describe the benefits of international trade.
Public Health and Trade Policy
Globalization & Business opportunities
Chapter 21 Section 4 (Pgs ) Living in a World Economy
FTAA and Access to Medicines
US International Tax System By: Jimmy Claymore Shane Noel
Honors International Marketing Ms. Osteen
Trust Me, You Can Do It: Building A Successful Grassroots Campaign
Trade-related policies and access to medicines
SS6E2 The student will give examples of how voluntary trade benefits buyers and sellers in Latin America and the Caribbean and Canada.
Living in a World Economy
Presentation transcript:

PRIORITIZING HEALTH IN U.S. TRADE POLICY: A CASE EXAMPLE

2004 Political Crisis: Pharmaceuticals Public outcry about high drug prices Public outcry about high drug prices U.S. pays highest prices in the world U.S. pays highest prices in the world Reimportation proposals in U.S. Congress Reimportation proposals in U.S. Congress

Pharma Political Strategy: Trade Agreements A. Protect high prices in US market Block reimportation (“parallel importation”) Block reimportation (“parallel importation”) B. Maintain Intellectual Property structure in regional trade agreements with low/ middle-income countries “TRIPS-Plus” trade rules extend patents “TRIPS-Plus” trade rules extend patents Restrict production and sale of generics Restrict production and sale of generics Market to small number of wealthy individuals Market to small number of wealthy individuals

Australia Trade Agreement CPATH 2004: C aution Needed Analysis – U.S. Australia FTA: Could block reimporting lower priced drugs into US Could block reimporting lower priced drugs into US Challenges effective methods for controlling drug prices in Australia Challenges effective methods for controlling drug prices in Australia Could affect popular US drug price programs for VA, Medicaid, Medicare Could affect popular US drug price programs for VA, Medicaid, Medicare

Education & Outreach 2004 U.S.-Australia FTA U.S. Trade Representative U.S. Trade Representative Meetings/correspondence regarding specific provisions Meetings/correspondence regarding specific provisions U.S. Congress U.S. Congress Testimony before House Ways and Means Committee Testimony before House Ways and Means Committee Meetings with Congressional Trade and Health staff Meetings with Congressional Trade and Health staff Congressional Committees on Health, V.A. Congressional Committees on Health, V.A. Civil Society Civil Society Widely disseminated analysis to national and local domestic organizations which focused on increasing access to affordable medicine in U.S. Widely disseminated analysis to national and local domestic organizations which focused on increasing access to affordable medicine in U.S.

Senator Clinton Town Hall – N.Y. “Is the Senator considering supporting the Australia Free Trade Agreement, which could prohibit drug reimportation into the United States?” “Is the Senator considering supporting the Australia Free Trade Agreement, which could prohibit drug reimportation into the United States?” Senior, Constituent Senior, Constituent

Congress Objects FTA achieves corporate policy agenda without public debate FTA achieves corporate policy agenda without public debate Kennedy, Schumer, McCain, Gutknecht: Get public health representation! Kennedy, Schumer, McCain, Gutknecht: Get public health representation! Bob Graham, Strickland, Evans: Protect VA! Bob Graham, Strickland, Evans: Protect VA! Allen, Rangel, Levin: Never again! Allen, Rangel, Levin: Never again!

Sen. Charles Schumer It has become clear in recent weeks that the pharmaceutical industry has not only done everything in its power to thwart drug reimportation legislation before this Congress, but now they have hijacked the trade agreement negotiation process as well. That practice has to end. It has become clear in recent weeks that the pharmaceutical industry has not only done everything in its power to thwart drug reimportation legislation before this Congress, but now they have hijacked the trade agreement negotiation process as well. That practice has to end. The provision is nothing more than a backdoor opportunity to protect the big pharmaceutical companies' profits and keep drug prices high for U.S. consumers The provision is nothing more than a backdoor opportunity to protect the big pharmaceutical companies' profits and keep drug prices high for U.S. consumers

U.S. Trade Policy Change Australia: Congress draws line in the sand Australia: Congress draws line in the sand Vitter/Stabenow/Northup/DeLauro bills Vitter/Stabenow/Northup/DeLauro bills Ban using trade agreements to address drug reimportation Ban using trade agreements to address drug reimportation Call for consumer representatives in policy Call for consumer representatives in policy U.S. ceases to propose trade rules banning drug importation U.S. ceases to propose trade rules banning drug importation

Vital Human Services for Sale “Some kinds of public policy choices should be decided by democratically elected governments, not by unelected trade bureaucrats.” “Some kinds of public policy choices should be decided by democratically elected governments, not by unelected trade bureaucrats.” U.S. Senator Jon Corzine (D-NJ) U.S. Senator Jon Corzine (D-NJ)

Elements for Change Transparency Transparency Publicly accessible analysis and debate of trade proposals Publicly accessible analysis and debate of trade proposals Accountability Accountability Communication with Congressional decision-makers, including in their districts linking trade and health Communication with Congressional decision-makers, including in their districts linking trade and health Opportunity and Timing Opportunity and Timing Public attention and national debate on the issue Public attention and national debate on the issue (in this case affordability of drugs in U.S.) (in this case affordability of drugs in U.S.)

FTAA: Free Trade Area of the Americas - DEFEATED Launched in Negotiating deadline: 2005 Launched in Negotiating deadline: 2005 NAFTA for all 34 countries in North, Central, South America and the Caribbean (except Cuba) NAFTA for all 34 countries in North, Central, South America and the Caribbean (except Cuba) Most comprehensive proposed trade agreement in history, would have affected more than 800 million people Most comprehensive proposed trade agreement in history, would have affected more than 800 million people